Managing Complexity. Improving Lives.

COVID-19 Resources

We are so grateful for all first responders, healthcare professionals and essential employees' efforts in the battle against COVID-19. We believe in listening to needs and delivering solutions and we are proud to join you in the fight. We are doing a variety of things to make a difference.

Learn More

Corporate Social Responsibility Report

Mallinckrodt releases its first annual Corporate Social Responsibility report that illustrates a wide-ranging commitment to corporate stewardship.

Read More

A Diverse and Growing Pipeline

Mallinckrodt is focused on developing innovative therapies and cutting-edge technologies for patients with severe and critical conditions and has products spanning all phases of clinical development.

View Our Pipeline

Agreement in Principle for Global Opioid Settlement

Mallinckrodt Announces Agreement in Principle for Global Opioid Settlement and Associated Debt Refinancing Activities

Read More
Pills

Prescription Drug Abuse Prevention

Mallinckrodt supports a broad range of programs that encourage the appropriate prescribing, use, storage and disposal of pain medications.

Learn More
laboratory test tubes

Mallinckrodt's Pledge on Drug Pricing and Innovation

We pledge to create the best possible healthcare at the lowest possible cost for the greatest number of people.

Our Pledge
senior couple

Our Products

Building on our heritage and distinctive capabilities, our world-class development and formulation expertise bring medical solutions to the marketplace.

Get Product Information
Mallinckrodt building

NYSE: MNK

as of August 04 2020 4:10 PM (ET) $1.62 -0.64 / -28.32%

Local time: 03:41:57 PM

  • Open: $1.5
  • High: $1.81
  • Low: $1.48
  • Volume: 28332920